- Business
- BDH Industries Limited (BDH.BO), founded in 1935 as Bombay Drug House and headquartered in Mumbai, India, manufactures and exports a wide range of therapeutic pharmaceutical formulations; its core products encompass antifungals, antibiotics, anticancer agents, antidiabetics, antidepressants, antiulcerants, antimalarials, anti-inflammatories, analgesics, antispasmodics, anti-tuberculosis drugs, cardiovascular medications, dermatologicals, NSAIDs, psychotropics, trichologicals, vitamins and minerals, as well as skin protectives, smootheners, and specialized offerings like SOULFIL for erectile dysfunction treatment; the company operates as a full-service contract manufacturing organization (CMO) providing tablets, capsules, topical creams and ointments, injections, oral suspensions, eye drops, dry syrups, and associated packaging solutions across pharmaceuticals and oncological products. BDH Industries serves domestic and international markets, with operations in India and exports to global destinations, and maintains a renewable energy segment through two wind turbines totaling 0.8 MW capacity in Jaisalmer, Rajasthan. In recent developments, the company continues steady growth as a reliable CMO partner for leading pharmaceutical firms, held its 35th Annual General Meeting proceedings released on August 7, 2025, scheduled a Board meeting for November 12, 2025 to consider financial results, and sustains stable promoter shareholding at approximately 49.7% as of September 2025.